Human liver immunohistochemistry

MB Miriam Bosch
NK Nina Kallin
SD Sainitin Donakonda
JZ Jitao David Zhang
HW Hannah Wintersteller
SH Silke Hegenbarth
KH Kathrin Heim
CR Carlos Ramirez
AF Anna Fürst
EL Elias Isaac Lattouf
MF Martin Feuerherd
SC Sutirtha Chattopadhyay
NK Nadine Kumpesa
VG Vera Griesser
JH Jean-Christophe Hoflack
JS Juliane Siebourg-Polster
CM Carolin Mogler
LS Leo Swadling
LP Laura J. Pallett
PM Philippa Meiser
KM Katrin Manske
GA Gustavo P. de Almeida
AK Anna D. Kosinska
IS Ioana Sandu
AS Annika Schneider
VS Vincent Steinbacher
YT Yan Teng
JS Julia Schnabel
FT Fabian Theis
AG Adam J. Gehring
AB Andre Boonstra
HJ Harry L. A. Janssen
MV Michiel Vandenbosch
EC Eva Cuypers
Rupert Öllinger
TE Thomas Engleitner
RR Roland Rad
KS Katja Steiger
AO Annette Oxenius
WL Wan-Lin Lo
VK Victoria Klepsch
GB Gottfried Baier
BH Bernhard Holzmann
MM Mala K. Maini
RH Ron Heeren
PM Peter J. Murray
RT Robert Thimme
CH Carl Herrmann
UP Ulrike Protzer
JB Jan P. Böttcher
request Request a Protocol
ask Ask a question
Favorite

Human liver samples (formalin-fixed, paraffin embedded, n = 21; ethical approval: 518/19 S) were double-stained by RNAscope (CXCR6) and CD3 (MRQ39, 1:1,500). Briefly, after deparaffinization and standard pretreatment, slides were incubated with RNA probes for CXCR6 (468468, ACD, Bio-Techne), detected with a RNAscope 2.5 Leica Assay-brown (Leica Biosystems) followed by incubation with a primary antibody against CD3 (103R-95, CellMarque) and detection with a Bond Polymer Refine Red Detection Kit (Leica Biosystems) on a Bond Rxm system (Leica Biosystems). All slides were counterstained with haematoxylin, cover slipped and digitalized using an AT2 scanner (Leica Biosystems). The study was conducted according to federal guidelines, local ethics committee regulations of the Technical University of Munich, Germany (no. 518/19 S-SR)

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A